Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $9.8652W HIGH $18.43
Volume
8.68 M
Value Traded
216.41 M
Short % Float
3.74%
0%Week
+4.74%1 Month
+0.63%3 Month
+24.48%6 Month
+7.42%5 Year
+33,200%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
20.03 B
EPS (TTM)
-0.36
P/E Ratio
-
Ent. Value
32.50 B
Total Shares
1.15 B
Float Shares
1.12 B
Insiders
2.07%
Institutions
92.70%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
VTRS Catalyst Timeline
Dated clinical, regulatory and corporate events for Viatris Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Viatris Inc.
333Total events
10Upcoming
119Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲AcquisitionCorporate
Viatris agrees to acquire Pacira BioSciences for $36.50/share in cash ($1.65B equity value)
▲FDA ApprovalWAKIXApprovedFDA Decision
Japan MHLW approves WAKIX for EDS associated with OSAS
excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstructionsource ↗
▲Partnership / LicenseTyrvayaApprovedCorporate
Sale of global rights for Tyrvaya to Harrow, Inc.
▲FDA ApprovalFDA Decision
FDA approved Gwyn Lo contraceptive patch
prevention of pregnancy in women with BMI < 30 kg/m2source ↗
▲Full ResultsClinical Data
Phase 3 Luminous Study results reported in approval announcement
contraceptionsource ↗
▲Topline ReadoutVR-205Clinical Data
Positive top-line results from Phase 3 study of VR-205 in Japanese adults with primary IgAN
primary immunoglobulin A nephropathysource ↗
▲Primary Endpoint MetVR-205Clinical Data
Primary endpoint met: 33.75% reduction in UPCR at 9 months
primary immunoglobulin A nephropathysource ↗
◆FDA Approvallow-dose estrogen weekly patchFiledFDA Decision
Anticipated FDA approval for low-dose estrogen weekly patch
hormone therapysource ↗
▲FDA Approvalferric carboxymaltose injectionApprovedFDA Decision
FDA approval of generic ferric carboxymaltose injection
iron deficiency anemia and non-dialysis dependent chronic kidney diseasesource ↗
▲Topline ReadoutVR-205Clinical Data
Positive top-line results from Phase 3 trial of VR-205
primary immunoglobulin A nephropathysource ↗
▲FDA Filing Accepted107A-02FiledRegulatory Filing
FDA accepts NDA for fast-acting meloxicam
moderate-to-severe acute painsource ↗
◆Oral PresentationPresentation
Viatris to present at Bank of America Securities 2026 Healthcare Conference
◆Management ChangeCorporate
CFO Theodora Mistras to depart; Paul Campbell named interim CFO effective May 8, 2026
◆Poster PresentationMR-100A-01 (low-dose estrogen weekly contraceptive patch)ApprovedPresentation
Comparison of multiple-dose pharmacokinetics of norelgestromin and ethinyl estradiol following MR-100A-01 vs oral contraceptive tablets
contraceptionsource ↗
▲Oral Presentationlow-dose estrogen weekly patchFiledPresentation
Six abstracts on low dose estrogen weekly patch presented at ACOG 2026
contraceptionsource ↗
◆Oral PresentationMR-141FiledPresentation
VEGA-3 data to be presented at ARVO meeting
presbyopiasource ↗
▲FDA Filing AcceptedMR-100A-01 (low-dose estrogen weekly contraceptive patch)ApprovedRegulatory Filing
FDA accepted NDA for low-dose estrogen CHC weekly patch under 505(b)(2) pathway
contraceptionsource ↗
◆Oral PresentationMR-141FiledPresentation
Phentolamine Ophthalmic Solution Provides Durable Improvement in Distance Corrected Near Vision for Presbyopic Patients in a Phase 3 Study
presbyopiasource ↗
◆Oral PresentationMR-142Presentation
Phase 3 Randomized Controlled Study of Phentolamine Ophthalmic Solution in Post-Refractive Surgery Patients with Impaired Mesopic Vision
visual disturbances in low light conditions in post-refractive surgery patientssource ↗
◆Poster PresentationRYZUMVIApprovedPresentation
Optical Impact of Reversing Pharmacologically Induced Mydriasis on Image Quality
pharmacologically-induced mydriasissource ↗
◆Poster PresentationPresentation
Changes in Tear Meniscus Height after a Single-Dose of Varenicline Solution Nasal Spray in Healthy Japanese Adult Volunteers
healthy Japanese adultssource ↗
●Full ResultsMR-141FiledClinical Data
Full results from VEGA-3 Phase 3 study of MR-141 for presbyopia presented at ASCRS 2026
presbyopiasource ↗
◆Oral PresentationMR-141FiledPresentation
VEGA-3 data to be presented at ASCRS meeting
presbyopiasource ↗
▲Other Regulator MilestoneEffexorApprovedEx-US Regulatory
MHLW approval of Effexor for GAD in Japan
generalized anxiety disorder (GAD)source ↗
◆Timing GuidancePresentation
Investor Event to discuss long-term outlook and portfolio strategy
▲FDA ApprovalFDA Decision
Effexor SR approved in Japan for generalized anxiety disorder
generalized anxiety disordersource ↗
▼Restructuring LayoffsCorporate
Enterprise-wide strategic review results: global workforce reduction of up to ~10%
▲FDA Filing AcceptedMR-141FiledRegulatory Filing
FDA accepted sNDA for MR-141 for presbyopia
presbyopiasource ↗
◆Poster PresentationPresentation
Presentation of new safety and efficacy data from GA Depot Phase II study in PPMS at ACTRIMS Forum 2026
primary progressive multiple sclerosis (PPMS)source ↗
▲Manufacturing MilestoneCMC / Inspection
Israeli Ministry of Health GMP approval received for GA Depot
▲FDA Filing AcceptedMR-141FiledRegulatory Filing
FDA accepted sNDA for MR-141 for presbyopia
presbyopiasource ↗
▼Supply DisruptionCMC / Inspection
Fire at Nashik, India manufacturing facility; production suspended until April 2026
●Other Regulator MilestoneInpefaApprovedEx-US Regulatory
Regulatory filings submitted in Canada, Australia, and Mexico
heart failuresource ↗
◆Oral PresentationPresentation
Viatris presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchEffexorApprovedPost-Market
Launch of Effexor for generalized anxiety disorder in Japan
generalized anxiety disordersource ↗
▲Partnership / LicenseCorporate
Sale of Viatris' equity stake in Biocon Biologics to Biocon Limited
▲FDA ApprovalFDA Decision
FDA approval of Octreotide Acetate for Injectable Suspension
acromegaly and complications associated with specific cancerous tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How VTRS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-29 | MR-100A-01 (investigational low-dose estrogen CHC weekly patch) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
6
Drugs Scored
rNPV / MCap
Top Drug
Top 5%
Mid Cap(rank 34 of 656)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines from the latest annual filing)
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Lipitor | |||
| Norvasc | |||
| Lyrica | |||
| EpiPen Auto-Injectors | |||
| Viagra | |||
| Creon | |||
| Celebrex | |||
| Zoloft | |||
| Yupelri | |||
| Effexor | |||
| Xalabrands | |||
| Amitiza |
Top 12 of 14 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| system containing progestin Small moleculeNCT06672016 | Female Contraception | Phase 3 | ACTIVE NOT_RECRUITING | 1,630 | May 1, 2027 | ||||||
| Selatogrel Small moleculeNCT07615868 | Chronic Coronary Syndrome | Phase 1 | RECRUITING | 20 | Oct 1, 2026 | ||||||
| cenerimod Small moleculeNCT07201129 | Nephritis, Lupus | Phase 3 | RECRUITING | 300 | Feb 1, 2030 | ||||||
| cenerimod Small moleculeNCT05648500 | Systemic Lupus Erythematosus | Phase 3 | ACTIVE NOT_RECRUITING | 2,133 | Sep 30, 2027 | ||||||
| cenerimod Small moleculeNCT07266090 | SLE - Systemic Lupus Erythematosus | Phase 2 | ACTIVE NOT_RECRUITING | 15 | Oct 8, 2027 | ||||||
| Selatogrel Small moleculeNCT03487445 | Acute Myocardial Infarction | Phase 3 | COMPLETED | 25,048 | Nov 10, 2018 | ||||||
| Selatogrel Small moleculeCompletedNCT03384966 | Stable Coronary Artery Disease | Phase 2 | COMPLETED | 346 | Sep 18, 2018 | ||||||
| ACT-246475 Small moleculeCompletedNCT03814200 | Undisclosed | Phase 1 | COMPLETED | 97 | Feb 19, 2019 | ||||||
| 107A-02 Small moleculeCompletedNCT05317312 | Acute Pain | Phase 3 | COMPLETED | 1,100 | Jun 20, 2022 | ||||||
| MR-130A-01 Small moleculeNCT06048536 | Contraception | Phase 2 | COMPLETED | 228 | Jan 18, 2024 | ||||||
| Combined contraceptives Small moleculeCompletedNCT04255277 | Undisclosed | Phase 1 | COMPLETED | 97 | Oct 18, 2021 | ||||||
| MYL-1401A Monoclonal antibodyMarketedNCT02714322 | Psoriasis | Phase 3 | COMPLETED | 294 | Mar 1, 2017 | ||||||
| Revefenacin Small moleculeMarketedNCT03095456 | Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | COMPLETED | 207 | Nov 25, 2017 | ||||||
| Azelastine Hydrochl./Fluticasone Prop. 0.137/ACTUAT Small moleculeMarketedNCT03599791 | Allergic Rhinitis | Phase 3 | COMPLETED | 900 | Sep 24, 2019 | ||||||
| Revefenacin Small moleculeMarketedNCT05046795 | COPD | Phase 3 | COMPLETED | 258 | Jul 26, 2023 | ||||||
| Revefenacin Small moleculeMarketedNCT03573817 | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | COMPLETED | 122 | Sep 25, 2018 | ||||||
| MR-100A-01 (low-dose estrogen weekly contraceptive patch) Small moleculeMarketedNCT05139121 | Contraception | Phase 3 | COMPLETED | 1,319 | Jan 15, 2025 | ||||||
| Trastuzumab Monoclonal antibodyMarketedNCT02472964 | Breast Cancer | Phase 3 | COMPLETED | 500 | Aug 1, 2018 | ||||||
| Ziprasidone Small moleculeMarketedNCT00257166 | Bipolar Disorder | Phase 3 | COMPLETED | 238 | Jul 1, 2007 | ||||||
| Pregabalin Small moleculeMarketedNCT00245609 | Dental Anxiety | Phase 2 | COMPLETED | 90 | Oct 1, 2006 | ||||||
| Treatment A: Azelastine 0.15% Small moleculeMarketedNCT06126952 | Seasonal Allergic Rhinitis | Phase 2 | COMPLETED | 84 | Mar 18, 2024 | ||||||
| Sertraline Small moleculeMarketedNCT00648856 | Undisclosed | Phase 1 | COMPLETED | 70 | Jan 1, 2003 | ||||||
| Levothyroxine Small moleculeMarketedNCT00648557 | Undisclosed | Phase 1 | COMPLETED | 65 | Mar 1, 2003 | ||||||
| Alprazolam Small moleculeMarketedNCT00650299 | Undisclosed | Phase 1 | COMPLETED | 66 | Aug 1, 2004 | ||||||
| Amlodipine and Benazepril Small moleculeMarketedNCT00649402 | Healhty | Phase 1 | COMPLETED | 64 | Jun 1, 2004 |
Clinical Trial Results
Readouts, endpoints and source filings for every VTRS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VR-205 | primary immunoglobulin A nephropathy | Phase 3 | 2026-06-29 | 33.75 percent reduction in geometric mean urine protein-to-creatinine ratio at 9 months compared to baseline; statistically significant and clinically meaningful reduction in UPCR at 6 and 12 months; significant improvement in estimated glomerular filtration rate; reductions in serum creatinine and urine albumin-to-creatinine ratio at 9 months; no study participants progressed to dialysis, kidney transplant or severe renal impairmentRead More | Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A NephropathyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Enrietti AndrewOfficer (See Remarks) | Option | 25,134 244,811 held | $0.00 | 08/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VTRS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.3 % | 3.18 M | 200.00 K |
VTRS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VTRS ranks across every disease it competes in
Competitive Position is a premium feature
See how VTRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVTRS News
VTRSViatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies
Viatris has announced its agreement to acquire Pacira BioSciences for $36.50 per share, totaling approximately $1.65 billion. This acquisition will add two established products, EXPAREL and ZILRETTA, to Viatris' portfolio, enhancing its capabilities in non-opioid pain therapies. The deal is anticipated to close by the end of 2026 and is expected to be financially beneficial for Viatris.
Read more →VTRSViatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
Viatris Inc. has announced that it will report its third-quarter 2026 financial results on November 5, 2026. The company will host a conference call and live webcast at 8:30 a.m. ET to discuss these results. Investors and the public can access the live event through the company's investor website or by phone.
Read more →VTRSViatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
Viatris Inc. has been named one of the World's Best Employers by Forbes for the sixth consecutive year, based on independent employee feedback. The recognition underscores the company's commitment to fostering a supportive and empowering workplace culture. Viatris continues to focus on diverse perspectives and collaborative problem-solving to enhance employee experience and patient care.
Read more →VTRSViatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
Viatris has received approval from Japan's Ministry of Health for WAKIX (pitolisant), a first-in-class treatment for excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. This approval addresses a significant unmet medical need in Japan and enhances Viatris' innovative portfolio. WAKIX is not classified as a controlled substance, providing a novel treatment option for patients.
Read more →VTRS▼ -7.7%on this news
Viatris Reports Second-Quarter 2026 Financial Results
Viatris Inc. reported its second-quarter 2026 financial results, showing a 5% increase in total revenues to $3.8 billion and an adjusted EBITDA of $1.2 billion, up 10% year-over-year. The company has raised its financial guidance for 2026, reflecting confidence in its operational execution and pipeline progress. However, it also reported a U.S. GAAP net loss of $119 million, driven by a non-cash charge related to the sale of product rights. Additionally, supply disruptions are expected to impact revenues in the second half of the year.
Read more →VTRSViatris Announces Quarterly Dividend
Viatris Inc. announced a quarterly dividend of $0.12 per share, payable on September 16, 2026. Shareholders of record as of August 21, 2026, will receive this dividend. The announcement reflects Viatris' commitment to providing value to its shareholders, despite potential risks outlined in their forward-looking statements.
Read more →VTRSViatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
Viatris has received FDA approval for Gwyn Lo™, a once-weekly contraceptive patch designed for women with a BMI below 30 kg/m². This low-dose estrogen patch aims to provide a discreet and effective contraceptive option. The approval is based on positive results from the Phase 3 Luminous Study, which demonstrated strong efficacy and safety. Gwyn Lo is expected to be commercially available later this year.
Read more →VTRSViatris to Report Second-Quarter 2026 Financial Results on August 6, 2026
Viatris Inc. has announced that it will report its second-quarter 2026 financial results on August 6, 2026. A conference call and live webcast will be held at 8:30 a.m. ET to discuss these results. Investors and the public can access the call via a dedicated website or by phone.
Read more →VTRSViatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
Viatris announced positive top-line results from a Phase 3 trial of VR-205 in Japanese adults with primary IgAN. The study met its primary endpoint, showing a significant reduction in urine protein-to-creatinine ratio and improvements in kidney function. The treatment was well tolerated, with no participants progressing to severe renal impairment. Viatris plans to submit a New Drug Application in Japan by the end of 2026.
Read more →VTRSU.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
Viatris announced that the FDA has accepted its New Drug Application for MR-107A-02, a fast-acting meloxicam aimed at treating moderate-to-severe acute pain. The FDA has set a PDUFA goal date of December 27, 2026. The NDA is backed by positive results from Phase 3 trials, demonstrating effective pain relief and a reduction in opioid usage. This development addresses a critical public health need for non-opioid pain management solutions.
Read more →VTRS▲ +9%on this news
Viatris Reports First-Quarter 2026 Financial Results
Viatris Inc. reported strong financial results for the first quarter of 2026, highlighting disciplined execution across global operations. CEO Scott A. Smith noted growth in key markets and reaffirmed the company's financial guidance for the year. The company anticipates generating significant cash, providing flexibility for capital allocation. Viatris is focused on enhancing its growth profile through new product launches and pipeline advancements.
Read more →VTRS▲ +9%on this newsshared move
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
Viatris Inc. has announced its participation in the Bank of America Securities 2026 Healthcare Conference, scheduled for May 12, 2026. The presentation will be accessible via a live webcast, with an archived version available afterward. This event reflects Viatris's ongoing commitment to healthcare innovation and investor relations.
Read more →VTRSViatris Announces Chief Financial Officer Transition Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFO
Viatris announced a transition in its Chief Financial Officer position, with Theodora 'Doretta' Mistras set to depart for a new opportunity. Paul Campbell, the current Chief Accounting Officer, has been appointed as the interim CFO effective May 8, 2026. Mistras will facilitate the transition until May 22, 2026, as the company seeks a permanent successor. The announcement emphasizes the company's preparation for sustainable growth and Campbell's expertise as crucial for continuity during this transition.
Read more →VTRSViatris Announces Chief Financial Officer Transition
Viatris Inc. announced the departure of Chief Financial Officer Theodora Mistras, who will leave for a new opportunity. Paul Campbell, the current Chief Accounting Officer, has been appointed as interim CFO effective May 8, 2026. Mistras will assist in the transition until May 22, 2026. The company is set to release its first-quarter financial results on May 7, 2026.
Read more →VTRSViatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
Viatris Inc. announced the presentation of six abstracts on its investigational low-dose estrogen combined hormonal contraceptive weekly patch at the 2026 ACOG Annual Clinical & Scientific Meeting. The presentations will showcase positive Phase 3 study results, including efficacy, safety, and adhesion performance. The FDA has accepted the New Drug Application for this patch, targeting a decision by July 30, 2026.
Read more →VTRSViatris to Report First Quarter 2026 Financial Results on May 7, 2026
Viatris Inc. has announced that it will report its first quarter 2026 financial results on May 7, 2026. The company will hold a webcast at 8:30 a.m. ET to discuss these results, inviting both investors and the public to participate. A replay of the webcast will be available on their website.
Read more →VTRSViatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Inc. announced the presentation of four abstracts at the 2026 ASCRS Annual Meeting, focusing on various ophthalmology studies. Highlights include full results from the Phase 3 VEGA-3 study on MR-141 for presbyopia and a Phase 1 study of varenicline nasal spray. The company also supports an educational symposium on pharmacological vision correction.
Read more →VTRSViatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris has received approval from Japan's Ministry of Health for Effexor® SR as the first treatment for adults with generalized anxiety disorder (GAD). This approval addresses a significant unmet need in Japan, where GAD affects approximately 7.6% of the population. The approval is based on a successful Phase 3 trial demonstrating the drug's efficacy and safety profile.
Read more →About Viatris Inc.
Headquarters1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317
BIOPHARMAWATCH ELITE PLUS
Trade the next VTRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime